- Home
- Cold Sore Treatment Market
Global Cold Sore Treatment Market - Industry Trends and Forecast to 2028
- Published Date: September, 2022 | Report ID: CLS-241 | No of pages: 365 | Format:
Global cold sore treatment market is projected to register a CAGR of 6.1% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028.
Market Segmentation:
Global Cold Sore Treatment Market, By Strain Type (Herpes Simplex Type-1 Virus, Herpes Simplex Type-2 Virus), Therapeutics Type (Antiviral Agents, Analgesic Agents, Others), Drug Type (Branded and Generics), Dosage Type (Oral, Topical and Others), End User (Hospitals, Homecare, Specialty Clinics and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Russia, Turkey, Switzerland, Belgium, Netherlands, Rest of Europe, Japan, China, South Korea, India, Australia and New Zealand, Singapore, Thailand, Hong-Kong, Taiwan, Indonesia, Malaysia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2028
Some of the major factors contributing to the growth of the global cold sore treatment market are:
Rise in geriatric population in South Africa
Application of point-of-care diagnostics in remote areas
Market Players:
The key market players for global cold sore treatment market are listed below:
Merix Pharmaceutical Corp.
GlaxoSmithKline plc
Amneal Pharmaceuticals LLC
Sun Pharmaceutical Industries Ltd.
Glenmark Pharmaceutical Inc., U.S.A. (A subsidiary OF Glenmark Pharmaceuticals Ltd.)
Zydus Pharmaceuticals, Inc.(A Subsidiary of Zydus Cadila)
Cipla Inc.
AiCuris
Ortho dermatologics (a division of bausch health Companies Inc.)
Foundation Consumer Healthcare
Squarex
Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.)
Aurobindo Pharma U.S.A. (A Subsidiary of Aurobindo Pharma)
WOCKHARDT
Novartis AG
Jubilant Cadista (a subsidiary of Jubilant Life Sciences Limited)
Hikma Pharmaceuticals PLC
Hetero Healthcare Limited
Apotex Inc.
Avanir Pharmaceuticals, Inc.
HRA Pharma
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION 44
1.1 OBJECTIVES OF THE STUDY 44
1.2 MARKET DEFINITION 44
1.3 OVERVIEW OF GLOBAL COLD SORE TREATMENT MARKET 44
1.4 LIMITATIONS 46
1.5 MARKETS COVERED 46
2 MARKET SEGMENTATION 49
2.1 MARKETS COVERED 49
2.2 GEOGRAPHICAL SCOPE 50
2.3 YEARS CONSIDERED FOR THE STUDY 51
2.4 CURRENCY AND PRICING 51
2.5 DBMR TRIPOD DATA VALIDATION MODEL 52
2.6 MULTIVARIATE MODELLING 55
2.7 THERAPEUTICS LIFELINE CURVE 56
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 56
2.9 DBMR MARKET POSITION GRID 58
2.10 VENDOR SHARE ANALYSIS 59
2.11 MARKET DRUG TYPE COVERAGE GRID 60
2.12 SECONDARY SOURCES 61
2.13 ASSUMPTIONS 61
3 EXECUTIVE SUMMARY 62
4 PIPELINE ANALYSIS 68
5 EPIDEMIOLOGY 69
6 MARKET OVERVIEW 70
6.1 DRIVERS 72
6.1.1 GROWING PREVALENCE OF COLD SORE INFECTION 72
6.1.2 PROLIFERATION IN MODES OF TRANSMISSION OF HERPES SIMPLEX VIRUS 73
6.1.3 INCREASING AWARENESS ABOUT SEXUALLY TRANSMITTED DISEASES 74
6.1.4 AVAILABILITY OF GENERIC DRUGS 75
6.1.5 RISING RATE OF HSV INFECTION AMONG WOMEN 75
6.2 RESTRAINTS 77
6.2.1 PATENT TERMINATION OF MARKETED DRUGS 77
6.2.2 RISKS OF OTHER DISEASES ASSOCIATED WITH COLD SORE 78
6.2.3 DEARTH OF AWARENESS ABOUT THE ONSET AND SYMPTOMS OF COLD SORE TREATMENT 78
6.3 OPPORTUNITIES 79
6.3.1 INCREASING DISPOSABLE INCOME 79
6.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS 79
6.3.3 INCREASING RESEARCH AND DEVELOPMENT 80
6.3.4 INCREASING USE OF COLD SORE PATCHES 80
6.4 CHALLENGES 82
6.4.1 RISE IN ALTERNATIVE TREATMENTS 82
6.4.2 EMERGENCE OF DRUGS RESISTANT TO ACYCLOVIR 82
6.4.3 SIDE EFFECTS ASSOCIATED WITH MEDICATIONS USED FOR TREATING COLD SORE 83
7 COVID-19 IMPACT ON GLOBAL COLD SORE TREATMENT MARKET 84
7.1 IMPACT ON PRICE 84
7.2 IMPACT ON DEMAND 84
7.3 IMPACT ON SUPPLY CHAIN 85
7.4 STRATEGIC DECISIONS FOR MANUFACTURERS 85
7.5 CONCLUSION 86
8 GLOBAL COLD SORE TREATMENT MARKET, BY STRAIN TYPE 87
8.1 OVERVIEW 88
8.2 HERPES SIMPLEX TYPE 1 VIRUS 91
8.3 HERPES SIMPLEX TYPE 2 VIRUS 91
9 GLOBAL COLD SORE TREATMENT MARKET, BY THERAPEUTICS 93
9.1 OVERVIEW 94
9.2 ANTIVIRAL AGENTS 98
9.2.1 ACYCLOVIR 99
9.2.2 FAMCICLOVIR 99
9.2.3 PENCICLOVIR 99
9.2.4 VALACYCLOVIR 99
9.2.5 DOCOSANOL 99
9.3 ANALGESIC AGENTS 99
9.3.1 CARMEX 100
9.3.2 HERPECIN 100
9.3.3 OTHERS 100
9.4 OTHERS 101
10 GLOBAL COLD SORETREATMENT MARKET, BY DRUG TYPE 102
10.1 OVERVIEW 103
10.2 GENERICS 107
10.2.1 OTC 109
10.3 BRANDED 109
10.3.1 PRESCRIPTION 110
10.3.2 OTC 110
11 GLOBAL COLD SORE TREATMENT MARKET, BY DOSAGE TYPE 111
11.1 OVERVIEW 112
11.2 ORAL 115
11.3 TABLETS 115
11.4 PILLS 116
11.5 TOPICAL 116
11.5.1 CREAM 118
11.5.2 OINTMENTS 118
11.5.3 GEL 118
11.5.4 SPRAY 118
11.6 OTHERS 118
12 GLOBAL COLD SORE TREATMENT MARKET, BY END USER 119
12.1 OVERVIEW 120
12.2 HOME CARE 123
12.3 HOSPITALS 123
12.4 SPECIALTY CLINICS 124
12.5 OTHERS 125
13 GLOBAL COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 126
13.1 OVERVIEW 127
13.2 HOSPITALS PHARMACY 131
13.3 ONLINE PHARMACY 131
13.4 RETAIL PHARMACY 132
14 GLOBAL COLD SORE TREATMENT MARKET, BY GEOGRAPHY 134
14.1 OVERVIEW 135
14.2 NORTH AMERICA 141
14.2.1 U.S. 149
14.2.2 CANADA 153
14.2.3 MEXICO 157
14.3 EUROPE 161
14.3.1 GERMANY 171
14.3.2 FRANCE 174
14.3.3 U.K. 177
14.3.4 ITALY 180
14.3.5 SPAIN 183
14.3.6 RUSSIA 186
14.3.7 SWITZERLAND 190
14.3.8 NETHERLAND 194
14.3.9 TURKEY 197
14.3.10 IRELAND 201
14.3.11 BELGIUM 204
14.3.12 POLAND 207
14.3.13 AUSTRIA 210
14.3.14 NORWAY 213
14.3.15 HUNGARY 216
14.3.16 LITHUANIA 219
14.3.17 REST OF EUROPE 222
14.4 ASIA PACIFIC 223
14.4.1 CHINA 232
14.4.2 JAPAN 235
14.4.3 INDIA 238
14.4.4 AUSTRALIA 241
14.4.5 SOUTH KOREA 244
14.4.6 SINGAPORE 247
14.4.7 MALAYSIA 250
14.4.8 PHILIPPINESS 253
14.4.9 INDONESIA 256
14.4.10 THAILAND 259
14.4.11 VIETNAM 262
14.4.12 REST OF ASIA-PACIFIC 265
14.5 SOUTH AMERICA 266
14.5.1 BRAZIL 274
14.5.2 ARGENTINA 277
14.5.3 PERU 281
14.5.4 REST OF SOUTH AMERICA 284
14.6 MIDDLE EAST & AFRICA 285
14.6.1 SOUTH AFRICA 291
14.6.2 EGYPT 294
14.6.3 SAUDI ARABIA 298
14.6.4 ISRAEL 301
14.6.5 UAE 305
14.6.6 KUWAIT 309
14.6.7 REST OF MIDDLE EAST & AFRICA 313
15 GLOBAL COLD SORE TREATMENT MARKET: COMPANY LANDSCAPE 314
15.1 COMPANY SHARE ANALYSIS: GLOBAL 314
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 315
15.3 COMPANY SHARE ANALYSIS: EUROPE 316
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 317
16 SWOT 318
17 COMPANY PROFILE 319
17.1 GLAXOSMITHKLINE PLC 319
17.1.1 COMPANY SNAPSHOT 319
17.1.2 REVENUE ANALYSIS 319
17.1.3 COMPANY SHARE ANALYSIS 320
17.1.4 PRODUCT PORTFOLIO 320
17.1.5 RECENT DEVELOPMENTS 320
17.2 ORTHO DERMATOLOGICS (A DIVISION OF BAUSCH HEALTH COMPANIES INC.) 322
17.2.1 COMPANY SNAPSHOT 322
17.2.2 REVENUE ANALYSIS 322
17.2.3 COMPANY SHARE ANALYSIS 323
17.2.4 PRODUCT PORTFOLIO 323
17.2.5 RECENT DEVELOPMENTS 323
17.3 FOUNDATION CONSUMER HEALTHCARE 325
17.3.1 COMPANY SNAPSHOT 325
17.3.2 COMPANY SHARE ANALYSIS 325
17.3.3 PRODUCT PORTFOLIO 326
17.3.4 RECENT DEVELOPMENT 326
17.4 NOVARTIS AG 327
17.4.1 COMPANY SNAPSHOT 327
17.4.2 REVENUE ANALYSIS 327
17.4.3 COMPANY SHARE ANALYSIS 328
17.4.4 PRODUCT PORTFOLIO 328
17.4.5 RECENT DEVELOPMENT 328
17.5 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.) 329
17.5.1 COMPANY SNAPSHOT 329
17.5.2 REVENUE ANALYSIS 329
17.5.3 PRODUCT PORTFOLIO 330
17.5.4 RECENT DEVELOPMENTS 330
17.6 AMNEAL PHARMACEUTICALS LLC 331
17.6.1 COMPANY SNAPSHOT 331
17.6.2 REVENUE ANALYSIS 331
17.6.3 PRODUCT PORTFOLIO 332
17.6.4 RECENT DEVELOPMENTS 332
17.7 AICURIS GMBH & CO. KG 333
17.7.1 COMPANY SNAPSHOT 333
17.7.2 PRODUCT PORTFOLIO 333
17.7.3 RECENT DEVELOPMENTS 333
17.8 APOTEX INC. 335
17.8.1 COMPANY SNAPSHOT 335
17.8.2 PRODUCT PORTFOLIO 335
17.8.3 RECENT DEVELOPMENTS 335
17.9 AUROBINDO PHARMA USA (A SUBSIDIARY OF AUROBINDO PHARMA) 337
17.9.1 COMPANY SNAPSHOT 337
17.9.2 REVENUE ANALYSIS 337
17.9.3 PRODUCT PORTFOLIO 338
17.9.4 RECENT DEVELOPMENTS 338
17.10 CIPLA LIMITED 339
17.10.1 COMPANY SNAPSHOT 339
17.10.2 REVENUE ANALYSIS 339
17.10.3 PRODUCT PORTFOLIO 340
17.10.4 RECENT DEVELOPMENTS 340
17.11 GLENMARK PHARMACEUTICALS, INC., USA (A SUBSIDIARY OF GLENMARK PHARMACEUTICAL LTD.) 341
17.11.1 COMPANY SNAPSHOT 341
17.11.2 REVENUE ANALYSIS 341
17.11.3 PRODUCT PORTFOLIO 342
17.11.4 RECENT DEVELOPMENTS 342
17.12 HIKMA PHARMACEUTICALS PLC 343
17.12.1 COMPANY SNAPSHOT 343
17.12.2 REVENUE ANALYSIS 343
17.12.3 PRODUCT PORTFOLIO 344
17.12.4 RECENT DEVELOPMENTS 344
17.13 HRA PHARMA 345
17.13.1 COMPANY SNAPSHOT 345
17.13.2 PRODUCT PORTFOLIO 345
17.13.3 RECENT DEVELOPMENTS 345
17.14 HETERO HEALTHCARE LIMITED 347
17.14.1 COMPANY SNAPSHOT 347
17.14.2 PRODUCT PORTFOLIO 347
17.14.3 RECENT DEVELOPMENT 347
17.15 JUBILANT CADISTA (A SUBSIDIARY OF JUBILANT LIFE SCIENCES LIMITED) 348
17.15.1 COMPANY SNAPSHOT 348
17.15.2 REVENUE ANALYSIS 348
17.15.3 PRODUCT PORTFOLIO 349
17.15.4 RECENT DEVELOPMENT 349
17.16 MERIX PHARMACEUTICAL CORP. 350
17.16.1 COMPANY SNAPSHOT 350
17.16.2 PRODUCT PORTFOLIO 350
17.16.3 RECENT DEVELOPMENTS 350
17.17 SQAUREX 352
17.17.1 COMPANY SNAPSHOT 352
17.17.2 PRODUCT PORTFOLIO 352
17.17.3 RECENT DEVELOPMENT 352
17.18 SUN PHARMACEUTICAL INDUSTRIES LTD. 353
17.18.1 COMPANY SNAPSHOT 353
17.18.2 REVENUE ANALYSIS 353
17.18.3 PRODUCT PORTFOLIO 354
17.18.4 RECENT DEVELOPMENTS 354
17.19 VIATRIS INC. 355
17.19.1 COMPANY SNAPSHOT 355
17.19.2 PRODUCT PORTFOLIO 355
17.19.3 RECENT DEVELOPMENTS 356
17.20 WOCKHARDT 357
17.20.1 COMPANY SNAPSHOT 357
17.20.2 REVENUE ANALYSIS 357
17.20.3 PRODUCT PORTFOLIO 358
17.20.4 RECENT DEVELOPMENTS 358
17.21 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA) 359
17.21.1 COMPANY SNAPSHOT 359
17.21.2 REVENUE ANALYSIS 359
17.21.3 PRODUCT PORTFOLIO 360
17.21.4 RECENT DEVELOPMENTS 360
18 QUESTIONNAIRE 362
19 RELATED REPORTS 365
Segmentation
Short Description
Global Cold Sore Treatment Market, By Strain Type (Herpes Simplex Type-1 Virus, Herpes Simplex Type-2 Virus), Therapeutics Type (Antiviral Agents, Analgesic Agents, Others), Drug Type (Branded and Generics), Dosage Type (Oral, Topical and Others), End User (Hospitals, Homecare, Specialty Clinics and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Russia, Turkey, Switzerland, Belgium, Netherlands, Rest of Europe, Japan, China, South Korea, India, Australia and New Zealand, Singapore, Thailand, Hong-Kong, Taiwan, Indonesia, Malaysia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2028
Market Definition:
Cold sores or oral herpes are small blisters kind abrasions that occur due to the infection caused by the herpes simplex virus (HSV). Cold sores generally occur on the face, around the lips, chin, cheeks and nostrils. They generally cause pain and itching before they burst. HSV is one of the most common viruses found to affect the population and it is endemic throughout the world. Up to 90% of people around the world have at least one form of HSV.
Market Segmentation:
The cold sore treatment market is segmented into six notable segments which are based on the strain type, therapeutics type, drug type, dosage type, end user, distribution channel.
On the basis of strain type, the cold sore treatment market is segmented into herpes simplex type-1 virus (HSV) and herpes simplex type-2 virus (HSV)
On the basis by therapeutics, the cold sore treatment market is segmented into antiviral agents, analgesic agents and others
On the basis of drug type, the cold sore treatment market is segmented into branded and generics
On the basis of dosage type, the cold sore treatment market is segmented into oral, topical and others
On the basis of end user, the cold sore treatment market is segmented into hospitals, homecare, specialty clinics and others
On the basis of distribution channel, the cold sore treatment market is segmented into hospital pharmacy, retail pharmacy and online pharmacy
Market Players
The key market players for global cold sore treatment market are listed below:
Merix Pharmaceutical Corp.
GlaxoSmithKline plc
Amneal Pharmaceuticals LLC
Sun Pharmaceutical Industries Ltd.
Glenmark Pharmaceutical Inc., U.S.A. (A subsidiary OF Glenmark Pharmaceuticals Ltd.)
Zydus Pharmaceuticals, Inc.(A Subsidiary of Zydus Cadila)
Cipla Inc.
AiCuris
Ortho dermatologics (a division of bausch health Companies Inc.)
Foundation Consumer Healthcare
Squarex
Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.)
Aurobindo Pharma U.S.A. (A Subsidiary of Aurobindo Pharma)
WOCKHARDT
Novartis AG
Jubilant Cadista (a subsidiary of Jubilant Life Sciences Limited)
Hikma Pharmaceuticals PLC
Hetero Healthcare Limited
Apotex Inc.
Avanir Pharmaceuticals, Inc.
HRA Pharma
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.